Research / CL / Fundamental state Inspectable configuration
State dimensions Filing 0000021665-26-000042 General Corporate
Capex intensity 10th Own-history percentile · N=20
Evidence method Level · gp.fundamentals.capex_revenue_ratio
2.39% · OPTIONAL · VALID
Operating cash generation 50th Own-history percentile · N=20
Evidence method Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
18.56% · OPTIONAL · VALID
Share-count growth 15th Own-history percentile · N=20
Evidence method Yoy · gp.fundamentals.shares_outstanding
-1.37% · CORE · VALID
Revenue growth 50th Own-history percentile · N=20
Evidence method Yoy · gp.fundamentals.revenue
4.91% · CORE · VALID
Inventory pressure 60th Own-history percentile · N=20
Evidence method Level · gp.fundamentals.inventory_revenue_ratio
40.68% · OPTIONAL · VALID
Gross margin 100th Own-history percentile · N=20
Evidence method Level · gp.fundamentals.gross_margin
61.48% · CORE · VALID
Operating margin 15th Own-history percentile · N=20
Evidence method Level · gp.fundamentals.operating_margin
18.95% · CORE · VALID
SBC intensity 60th Own-history percentile · N=20
Evidence method Level · gp.fundamentals.sbc_revenue_ratio
0.71% · OPTIONAL · VALID
As-filed lineage Fundamental state history Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History 37 states Self-history eligible
Sep 30, 2021 9/9 normalized Level 3 Dec 31, 2021 8/9 normalized Level 3 Mar 31, 2022 9/9 normalized Level 3 Jun 30, 2022 9/9 normalized Level 3 Sep 30, 2022 9/9 normalized Level 3 Dec 31, 2022 8/9 normalized Level 3 Mar 31, 2023 9/9 normalized Level 3 Jun 30, 2023 9/9 normalized Level 3 Sep 30, 2023 9/9 normalized Level 3 Dec 31, 2023 8/9 normalized Level 3 Mar 31, 2024 9/9 normalized Level 3 Jun 30, 2024 9/9 normalized Level 3 Sep 30, 2024 9/9 normalized Level 3 Dec 31, 2024 8/9 normalized Level 3 Mar 31, 2025 9/9 normalized Level 3 Jun 30, 2025 8/8 normalized Level 3 Sep 30, 2025 8/8 normalized Level 3 Dec 31, 2025 9/9 normalized Level 3 Mar 31, 2026 8/8 normalized Level 3 Jun 30, 2026 8/8 normalized Level 4 Period transition
What moved in the state? Capex Intensity Decreased
Previous 2.59%
Current 2.39%
Delta -0.20% Cash Generation Increased
Previous 14.03%
Current 18.56%
Delta 4.53% Dilution Decreased
Previous -1.26%
Current -1.37%
Delta -0.10% Growth Decreased
Previous 8.41%
Current 4.91%
Delta -3.50% Inventory Pressure Increased
Previous 39.18%
Current 40.68%
Delta 1.50% Margin Increased
Previous 60.59%
Current 61.48%
Delta 0.89% Profitability Increased
Previous 18.11%
Current 18.95%
Delta 0.84% Sbc Intensity Decreased
Previous 0.75%
Current 0.71%
Delta -0.04% Self-history only Previous similar states Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Mar 31, 2026
Similarity 81%
Compared 8 dimensions
Coverage 100% Growth 35.0 · Margin 20.0 · Dilution 5.0 · Profitability 5.0 · Sbc Intensity 0.0 · Capex Intensity 15.0 · Cash Generation 25.0 · Inventory Pressure 15.0 Jun 30, 2024
Similarity 79%
Compared 8 dimensions
Coverage 100% Growth 15.0 · Margin 20.0 · Dilution 26.2 · Profitability 35.0 · Sbc Intensity 25.0 · Capex Intensity 20.0 · Cash Generation 10.0 · Inventory Pressure 5.0 Jun 30, 2025
Similarity 72%
Compared 8 dimensions
Coverage 100% Growth 35.0 · Margin 40.0 · Dilution 45.0 · Profitability 30.0 · Sbc Intensity 20.0 · Capex Intensity 5.0 · Cash Generation 5.0 · Inventory Pressure 10.0 Dec 31, 2019
Similarity 71%
Compared 6 dimensions
Coverage 75% Margin 44.4 · Profitability 7.2 · Sbc Intensity 26.7 · Capex Intensity 23.3 · Cash Generation 16.7 · Inventory Pressure 37.8 Dec 31, 2020
Similarity 69%
Compared 7 dimensions
Coverage 88% Growth 30.0 · Margin 7.7 · Profitability 46.5 · Sbc Intensity 13.8 · Capex Intensity 43.8 · Cash Generation 11.5 · Inventory Pressure 36.9 Research Graph
Related governed research Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.